Etevritamab

DB17211InvestigationalProtein Based Therapies

Etevritamab: Overview.

Mechanism: Pharmacologically active on Epidermal growth factor receptor and T-cell surface glycoprotein CD3
Curator reviewed
Also known as: anti-EGFRvIII x anti-CD3 bispecific T cell engager antibody construct · Anti-egfrviii/cd3 bite antibody amg 596 · IMMUNOGLOBULIN SCFV-SCFV, ANTI-(HOMO SAPIENS EGFR (EPIDERMAL GROWTH FACTOR RECEPTOR, RECEPTOR TYROSINE-PROTEIN KINASE ERBB-1, ERBB1, HER1, HER-1, ERBB) VARIANT III (EGFRVIII)) AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), MONOCLONAL ANTIBODY SINGLE · IMMUNOGLOBULIN, BISPECIFIC, ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III) (HUMAN MONOCLONAL EGFRVIII BISPECIFIC 1 SINGLE-CHAIN VARIABLE FRAGMENT VH1-(GGGGS)3-VL1) FUSION PROTEIN WITH PEPTIDE LINKER (GGGGS) FUSION PROTEIN WITH IMMUNOGLOBULIN A
Code names: AMG-596

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Etevritamab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.